{"aliases":[{"type":"CASRegistryName","name":"909395-70-6"},{"type":"USBrandName","name":"Evenity"},{"type":"Synonym","name":"romosozumab-aqqg"}],"definition":{"html":"A recombinant humanized immunoglobulin G2 (IgG2) monoclonal antibody directed against sclerostin, with anti-osteoporotic activity. Upon administration, romosozumab targets, binds to and inhibits the activity of sclerostin, a regulatory factor in bone metabolism. This stimulates osteoblastic activity, increases bone formation and, to a lesser extent, decreases bone resorption This may increase trabecular and cortical bone mass and improve bone structure and strength. Altogether, this may decrease the risk of fractures. Sclerostin, a negative regulator of bone formation secreted by osteocytes, inhibits Wnt signaling and suppresses osteoblast development and function.\t","text":"A recombinant humanized immunoglobulin G2 (IgG2) monoclonal antibody directed against sclerostin, with anti-osteoporotic activity. Upon administration, romosozumab targets, binds to and inhibits the activity of sclerostin, a regulatory factor in bone metabolism. This stimulates osteoblastic activity, increases bone formation and, to a lesser extent, decreases bone resorption This may increase trabecular and cortical bone mass and improve bone structure and strength. Altogether, this may decrease the risk of fractures. Sclerostin, a negative regulator of bone formation secreted by osteocytes, inhibits Wnt signaling and suppresses osteoblast development and function.\t"},"drugInfoSummaryLink":null,"nciConceptId":"C152246","nciConceptName":"Romosozumab","termId":812844,"name":"romosozumab","firstLetter":"r","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"romosozumab"}